Announcements Trials
Browse Landscape

Phase

Phase 2 2Phase 1 1

Status

Completed 2Unknown 1

Sponsor Class

INDUSTRY 2OTHER_GOV 1

Study Type

Interventional 3

Sponsor

Cancer Type

Tumor-Agnostic 3CNS 2Thoracic 1Head & Neck 1Genitourinary 1Gastrointestinal 1

Conditions

Neoplasms 3Neoplasm Metastasis 2Adenocarcinoma 2

Interventions

Surveys and Questionnaires 65pembrolizumab 56Gemcitabine 54Paclitaxel 51Blood Specimen Collection 45Carboplatin 44Bevacizumab 41Docetaxel 38Cisplatin 33Nivolumab 32Fluorouracil 31Capecitabine 28Radiotherapy 25Pemetrexed 25Irinotecan 25Standard of Care 24Interviews as Topic 24Magnetic Resonance Spectroscopy 23Leucovorin 22Erlotinib Hydrochloride 22atezolizumab 21Cetuximab 21Afatinib 21Oxaliplatin 19trametinib 18Exercise 18Ipilimumab 17Sorafenib 16Cyclophosphamide 16olaparib 15

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

3 trials
RecentStart dateEnrollment
Neoplasms × vandetanib × Tumor-Agnostic × Clear all
NCT00500292 2018-01-25

A Phase II Study of 2 Doses of ZD6474 (Vandetanib) in Combination With FOLFOX vs FOLFOX Alone for the Treatment of Colorectal Cancer

Sanofi

Phase 2 Completed
109 enrolled 8 charts
Tumor-Agnostic

Neoplasms

NCT00503711 2016-08-31

Phase I Chinese PK

Sanofi

Phase 1 Completed
36 enrolled
Tumor-Agnostic

Neoplasms

NCT02530411 2015-08-21

FURVA

Velindre NHS Trust

Phase 2 Unknown
160 enrolled
Tumor-Agnostic

Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡